August 9th, 2007
“Every hour there was at least one session I wished I could have attended, but the one I will single out here is “Give us your Data! Google’s effort to archive and distribute the world’s scientific datasets” by Noel Gorelick (formerly of NASA and now at Google). For a conference on the future of biology, technology, and science, meeting at Google’s global headquarters, this was a rare session that focused explicitly on how Google is changing the landscape. Rather, Google now is the landscape, and the success of SciFoo offers ample demonstration of that.” — George Dyson in Edge 219
Edge 219
No Comments | In: Business, Google | | #
December 11th, 2006
The World In 2007 | Towards immortality
From the Economist Magazine…
More and more drugs developed to treat disease are turning out also to offer the potential to “enhance” the cognitive powers of healthy people, and to push human life expectancy much further, perhaps to 115 years and beyond.
and covered on the Accelerating Future blog.
No Comments | In: Anti-Aging, Articles, Business, Ethics | | #
December 8th, 2006
From Venturewire today: In one of the largest acquisitions ever of a private biotech company, GlaxoSmithKline said this morning it agreed to buy venture-backed Domantis for about $454 million in cash.
Europe’s biggest drug maker said Domantis will become part of GSK’s Biopharmaceuticals Centre of Excellence for Drug Discovery while continuing to operate from laboratories in Cambridge, U.K.
One of Domantis’ major backers, 3i, said the deal will generate an internal rate of return of 100% on its investment. 3i first backed Domantis in 2004, leading a GBP17.5 million Series B round and then another GBP17 million to extend the round in December 2005.
Also investors in the company are Danish biopharmaceutical group Novo Nordisk, Mitsubishi subsidiary MC Life Science Ventures Inc., Peptech, Albany Ventures and MVM Ltd.
Large pharmaceutical companies have been throwing their cash around as of late to enhance their drug pipelines. Domantis develops antibody therapies based on the smallest functional binding units of human antibodies which means they can be administered orally, by inhalation and topically as well as by injection.
No Comments | In: Acquisition, Biotech, Business, Domantis, GlaxoSmithKline, Venture Capital | | #
August 3rd, 2006
The next 10 years of technology innovation will be unlike anything our world has ever seen. Corporations need to paddle like hell to catch this wave—or they might just be ripped asunder.
Download and read the full article excerpted from the August issue of Architecture and Governance Magazine.
No Comments | In: Articles, Business, Futurism | | #